Judy He
Overview
Clients rely on Judy to find targeted and efficient legal solutions to high-stakes intellectual property and licensing disputes. Judy has represented small and large companies across various industries, including pharmaceuticals, medical devices, agricultural technology, semiconductors, electronic cigarettes, and other consumer products, from pre-suit to post-trial/appeal. Her practice is primarily in federal district court litigation involving patents and trade secrets, and she also has experience with mediations, arbitrations, preliminary injunction hearings, and post-grant proceedings. In addition, Judy teaches legal writing as an adjunct legal writing professor at Loyola University Chicago School of Law.
Career & Education
- Department of Homeland Security
Extern, U.S. Immigration and Customs Enforcement Office of the Principal Legal Advisor, 2016
- Department of Homeland Security
- PILI Fellow at the Young Center for Immigrant Children’s Rights, 2017
- Managing Editor of Iowa Law Review, Volume 102, 2016 – 2017
- Judicial Intern to the Honorable Linnea E. Thompson in the Fourteenth Judicial Circuit of Illinois, 2015
- University of Iowa, B.A., With Honors, Chemistry, 2014
- University of Iowa, B.B.A., With Honors, Finance, 2014
- University of Iowa College of Law, J.D., 2017
- Illinois
- U.S. Patent and Trademark Office (USPTO)
- U.S. District Court for the Northern District of Illinois
- U.S. Court of Appeals for the Federal Circuit
- Supreme Court of the United States
- U.S. Court of Appeals for the Fifth Circuit
Professional Activities and Memberships
- Intellectual Property Law Association of Chicago (IPLAC)
- Board Member and Sponsorship Chair (2023-2024)
- Board Member and Programming Chair (2022-2023)
- Intellectual Property Owners Association (IPO)
- Vice Chair of U.S. Patent and Litigation Committee (2024)
- Secretary of Patent Litigation & Remedies Committee (2023)
- Red Shoe Society Chicago (RSS)
- Vice Chair of Communications Committee (2024)
- Public Interest Law Initiative (PILI), Young Professionals Board
- Immediate Chair (2023-2024)
- Chair (2022-2023)
- Chair-Elect (2021-2022)
- Vice Chair and Membership Chair (2020-2021)
- Chicago Women in IP (ChiWIP)
- Co-Chair of Community Involvement Committee (2023-2024)
- Women In Bio (WIB)
- National Membership Chair (2021-2023)
- National Immigrant Justice Center (NIJC)
- Associate Leadership Board Member (2023-current)
- ABA Section of Litigation Judicial Intern Opportunity Program (JIOP)
- Illinois Working Group Member (2021-current)
- Leadership Council on Legal Diversity (LCLD)
- Class Liaison for 2022 Pathfinders (2022-current)
- Intellectual Property Law Association of Chicago (IPLAC)
- Mandarin
Judy's Insights
Client Alert | 4 min read | 04.18.24
Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2]
Client Alert | 5 min read | 03.05.24
A Winning Streak? IRA’s Drug Price Negotiation Program Survives Again
Client Alert | 3 min read | 02.13.24
Recognition
- Super Lawyers, Illinois Rising Star for Intellectual Property Litigation, 2023
- NITA: Master Advocate, 2022; Advocate, 2018
- ABA Free Legal Answers: Pro Bono Leader, 2021 and 2022
- National Immigrant Justice Center: Rising Star, 2021
- ABA-Bloomberg BNA: Award for Excellence in the Study of Intellectual Property Law, 2017
- Boyd Service Award, Highest Honors, 2017
Judy's Insights
Client Alert | 4 min read | 04.18.24
Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2]
Client Alert | 5 min read | 03.05.24
A Winning Streak? IRA’s Drug Price Negotiation Program Survives Again
Client Alert | 3 min read | 02.13.24
Insights
Practices
Industries
Judy's Insights
Client Alert | 4 min read | 04.18.24
Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2]
Client Alert | 5 min read | 03.05.24
A Winning Streak? IRA’s Drug Price Negotiation Program Survives Again
Client Alert | 3 min read | 02.13.24
